721.3K XNAS Volume
XNAS 03 Apr, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Bernhardt G. Zeiher | Director | Purchase of securities on an exchange or from another person at price $ 3.70 per share. | 20 Mar 2025 | 10,000 | 10,000 | - | 3.7 | 37,005 | Common Stock |
| James M. Frates | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 68,420 | 301,884 | - | 0 | Common Stock | |
| James M. Frates | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 102,630 | 102,630 | - | - | Stock Option (right to buy) | |
| Camille L. Bedrosian | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 102,630 | 102,630 | - | - | Stock Option (Right to Buy) | |
| Camille L. Bedrosian | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 68,420 | 206,800 | - | 0 | Common Stock | |
| Joshua Cohen | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 270,177 | 270,177 | - | - | Stock Option (Right to Buy) | |
| Joshua Cohen | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 180,118 | 3,376,770 | - | 0 | Common Stock | |
| Justin Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 270,177 | 270,177 | - | - | Stock Option (right to buy) | |
| Justin Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 180,118 | 3,376,766 | - | 0 | Common Stock | |
| Gina M. Mazzariello | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 63,851 | 197,161 | - | 0 | Common Stock | |
| Gina M. Mazzariello | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 95,777 | 95,777 | - | - | Stock Option (right to buy) | |
| Joshua Cohen | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 3.17 per share. | 03 Mar 2025 | 4,595 | 3,196,652 | - | 3.2 | 14,549 | Common Stock |
| Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 3.15 per share. | 03 Mar 2025 | 4,595 | 3,196,648 | - | 3.2 | 14,483 | Common Stock |
| Gina M. Mazzariello | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 3.12 per share. | 03 Mar 2025 | 1,611 | 133,310 | - | 3.1 | 5,022 | Common Stock |
| Gina M. Mazzariello | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 3.15 per share. | 24 Feb 2025 | 4,169 | 134,921 | - | 3.2 | 13,145 | Common Stock |
| Justin Klee | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2025 | 36,310 | 0 | - | - | Stock Option (right to buy) | |
| Justin Klee | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.57 per share. | 05 Feb 2025 | 36,310 | 3,201,243 | - | 1.6 | 57,007 | Common Stock |
| Joshua Cohen | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 3.47 per share. | 03 Feb 2025 | 11,851 | 3,201,247 | - | 3.5 | 41,108 | Common Stock |
| Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 3.47 per share. | 03 Feb 2025 | 11,855 | 3,164,933 | - | 3.5 | 41,104 | Common Stock |
| Gina M. Mazzariello | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 3.49 per share. | 03 Feb 2025 | 3,678 | 139,090 | - | 3.5 | 12,839 | Common Stock |
| George Mclean Milne | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 24 Jan 2025 | 27,910 | 830,661 | - | 0 | Common Stock | |
| Joshua Cohen | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 4.05 per share. | 06 Jan 2025 | 7,471 | 3,213,098 | - | 4.0 | 30,232 | Common Stock |
| Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 4.04 per share. | 06 Jan 2025 | 7,471 | 3,176,788 | - | 4.0 | 30,202 | Common Stock |
| L. Camille Bedrosian | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 5.54 per share. | 02 Dec 2024 | 5,421 | 138,380 | - | 5.5 | 30,007 | Common Stock |
| Justin Klee | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2024 | 63,690 | 36,310 | - | - | Stock Option (right to buy) | |
| Justin Klee | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.57 per share. | 04 Nov 2024 | 63,690 | 3,184,259 | - | 1.6 | 99,993 | Common Stock |
| Camille L. Bedrosian | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 3.20 per share. | 30 Sep 2024 | 11,442 | 143,801 | - | 3.2 | 36,559 | Common Stock |
| Joshua Cohen | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 3.20 per share. | 30 Sep 2024 | 18,589 | 3,220,569 | - | 3.2 | 59,414 | Common Stock |
| Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 3.20 per share. | 30 Sep 2024 | 18,589 | 3,120,569 | - | 3.2 | 59,429 | Common Stock |
| Gina M. Mazzariello | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 3.20 per share. | 30 Sep 2024 | 8,709 | 142,768 | - | 3.2 | 27,840 | Common Stock |
| Joshua Cohen | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.57 per share. | 23 Sep 2024 | 1,857 | 3,239,158 | - | 1.6 | 2,915 | Common Stock |
| Joshua Cohen | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Sep 2024 | 1,857 | 0 | - | - | Stock Option (right to buy) | |
| James M. Frates | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.53 per share. | 12 Sep 2024 | 40,000 | 233,464 | - | 2.5 | 101,368 | Common Stock |
| Joshua Cohen | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2024 | 34,449 | 1,857 | - | - | Stock Option (right to buy) | |
| Joshua Cohen | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.57 per share. | 12 Sep 2024 | 34,449 | 3,237,301 | - | 1.6 | 54,085 | Common Stock |
| Karen Firestone | Director | Purchase of securities on an exchange or from another person at price $ 2.13 per share. | 05 Sep 2024 | 50,000 | 55,000 | - | 2.1 | 106,590 | Common Stock |
| George Mclean Milne | Director | Purchase of securities on an exchange or from another person at price $ 2.20 per share. | 03 Sep 2024 | 100,000 | 858,571 | - | 2.2 | 219,800 | Common Stock |
| George Mclean Milne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Daphne Quimi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Karen Firestone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Bernhardt G. Zeiher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 5,753 | 5,753 | - | - | Stock Option (right to buy) | |
| Gina M. Mazzariello | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 1.88 per share. | 15 May 2024 | 10,455 | 151,477 | - | 1.9 | 19,654 | Common Stock |
| Daphne Quimi | Director | Purchase of securities on an exchange or from another person at price $ 1.89 per share. | 14 May 2024 | 2,250 | 5,000 | - | 1.9 | 4,252 | Common Stock |
| Daphne Quimi | Director | Purchase of securities on an exchange or from another person at price $ 1.89 per share. | 14 May 2024 | 2,750 | 2,750 | - | 1.9 | 5,184 | Common Stock |
| James M. Frates | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 120,000 | 120,000 | - | - | Stock Option (right to buy) | |
| James M. Frates | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 91,180 | 225,964 | - | 0 | Common Stock | |
| Joshua Cohen | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 380,000 | 380,000 | - | - | Stock Option (right to buy) | |
| Joshua Cohen | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 179,850 | 3,202,852 | - | 0 | Common Stock | |
| Justin Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 179,850 | 3,139,158 | - | 0 | Common Stock | |
| Justin Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 380,000 | 380,000 | - | - | Stock Option (right to buy) | |
| Gina M. Mazzariello | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 110,000 | 110,000 | - | - | Stock Option (right to buy) | |
| Gina M. Mazzariello | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 80,560 | 161,932 | - | 0 | Common Stock | |
| Camille L. Bedrosian | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 96,910 | 155,243 | - | 0 | Common Stock | |
| Camille L. Bedrosian | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Bernhardt G. Zeiher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.73 per share. | 05 Mar 2024 | 1,792 | 134,784 | - | 18.7 | 33,560 | Common Stock |
| Joshua Cohen | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 18.73 per share. | 05 Mar 2024 | 4,135 | 3,023,002 | - | 18.7 | 77,440 | Common Stock |
| Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 18.73 per share. | 05 Mar 2024 | 4,135 | 2,959,308 | - | 18.7 | 77,440 | Common Stock |
| Gina M. Mazzariello | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 18.73 per share. | 05 Mar 2024 | 1,540 | 81,372 | - | 18.7 | 28,841 | Common Stock |
| Frates James M. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 40,000 | 152,035 | - | 0 | Common Stock | |
| Cohen Joshua | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 190,000 | 190,000 | - | - | Stock Option (right to buy) | |
| M. James Frates | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Gina M. Mazzariello | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 36,667 | 82,912 | - | 0 | Common Stock | |
| Klee Justin | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 126,667 | 2,963,443 | - | 0 | Common Stock | |
| Mazzariello M. Gina | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 55,000 | 55,000 | - | - | Stock Option (right to buy) | |
| Joshua Cohen | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 126,667 | 3,027,137 | - | 0 | Common Stock | |
| Justin Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 190,000 | 190,000 | - | - | Stock Option (right to buy) | |
| Mazzariello M. Gina | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 18.76 per share. | 23 Feb 2024 | 2,838 | 46,245 | - | 18.8 | 53,231 | Common Stock |
| Milne Mclean George | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 25 Jan 2024 | 9,100 | 758,571 | - | 0 | Common Stock | |
| George Mclean Milne | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Jan 2024 | 94,350 | 767,671 | - | 0 | Common Stock | |
| M. James Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.33 per share. | 09 Jan 2024 | 2,716 | 112,035 | - | 16.3 | 44,347 | Common Stock |
| Cohen Joshua | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 16.33 per share. | 09 Jan 2024 | 5,841 | 2,900,470 | - | 16.3 | 95,372 | Common Stock |
| Patrick Yeramian | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 16.33 per share. | 09 Jan 2024 | 2,812 | 205,605 | - | 16.3 | 45,915 | Common Stock |
| Klee Justin | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 16.33 per share. | 09 Jan 2024 | 5,841 | 2,836,776 | - | 16.3 | 95,372 | Common Stock |
| Olinger Margaret | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2023 | 25,000 | 44,577 | - | - | Stock Option (Right to Buy) | |
| Margaret Olinger | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.37 per share. | 27 Dec 2023 | 25,000 | 276,108 | - | 0.4 | 9,250 | Common Stock |
| Karen Firestone | Director | Purchase of securities on an exchange or from another person at price $ 14.97 per share. | 15 Dec 2023 | 4,000 | 5,000 | - | 15.0 | 59,880 | Common Stock |
| Camille L. Bedrosian | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Nov 2023 | 58,333 | 58,333 | - | 0 | Common Stock | |
| Camille L. Bedrosian | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Nov 2023 | 162,500 | 162,500 | - | - | Stock Option (Right to Buy) | |
| Joshua Cohen | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2023 | 63,694 | 36,306 | - | - | Stock Option (Right to Buy) | |
| Joshua Cohen | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.57 per share. | 16 Nov 2023 | 63,694 | 2,906,311 | - | 1.6 | 100,000 | Common Stock |
| James M. Frates | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Oct 2023 | 11,072 | 11,072 | - | 0 | Common Stock | |
| James M. Frates | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.88 per share. | 23 Aug 2023 | 18,165 | 106,341 | - | 6.9 | 124,975 | Common Stock |
| James M. Frates | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2023 | 18,165 | 363,835 | - | - | Stock Option (right to buy) | |
| James M. Frates | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.88 per share. | 23 Aug 2023 | 18,165 | 73,841 | - | 6.9 | 124,975 | Common Stock |
| James M. Frates | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2023 | 18,165 | 363,835 | - | - | Stock Option (right to buy) | |
| Gina M. Mazzariello | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 20.88 per share. | 15 Aug 2023 | 6,164 | 49,083 | - | 20.9 | 128,686 | Common Stock |
| Margaret Olinger | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.37 per share. | 12 Jul 2023 | 20,000 | 251,108 | - | 0.4 | 7,400 | Common Stock |
| Margaret Olinger | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2023 | 20,000 | 69,577 | - | - | Stock Option (Right to Buy) | |
| George Mclean Milne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 16,985 | 16,985 | - | - | Stock Option (right to buy) | |
| Daphne Quimi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 16,985 | 16,985 | - | - | Stock Option (right to buy) | |
| Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 16,985 | 16,985 | - | - | Stock Option (right to buy) | |
| Karen Firestone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 3,908 | 3,908 | - | - | Stock Option (right to buy) | |
| Margaret Olinger | Chief Commercial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 22 May 2023 | 1,580 | 231,108 | - | 0 | Common Stock | |
| Gina M. Mazzariello | Chief Legal Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 17 May 2023 | 500 | 55,247 | - | 0 | Common Stock | |
| James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 26.93 per share. | 16 May 2023 | 32,000 | 56,176 | - | 26.9 | 861,651 | Common Stock |
| James M. Frates | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2023 | 32,500 | 382,000 | - | - | Stock Option (right to buy) | |
| James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 27.60 per share. | 16 May 2023 | 500 | 55,676 | - | 27.6 | 13,800 | Common Stock |
| James M. Frates | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.88 per share. | 16 May 2023 | 32,500 | 88,176 | - | 6.9 | 223,600 | Common Stock |
| Patrick Yeramian | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2023 | 9,764 | 33,770 | - | - | Stock Option (right to buy) | |
| Patrick Yeramian | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2023 | 2,201 | 15,404 | - | - | Stock Option (right to buy) | |
| Patrick Yeramian | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 29.03 per share. | 15 May 2023 | 11,965 | 208,417 | - | 29.0 | 347,358 | Common Stock |
| Patrick Yeramian | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.88 per share. | 15 May 2023 | 9,764 | 220,382 | - | 6.9 | 67,176 | Common Stock |
| Patrick Yeramian | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.37 per share. | 15 May 2023 | 2,201 | 210,618 | - | 0.4 | 814 | Common Stock |
| Patrick Yeramian | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Apr 2023 | 4,718 | 43,534 | - | - | Stock Option (right to buy) | |
| Patrick Yeramian | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Apr 2023 | 44,861 | 17,605 | - | - | Stock Option (right to buy) | |
| Patrick Yeramian | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.53 per share. | 17 Apr 2023 | 49,279 | 208,717 | - | 30.5 | 1,504,660 | Common Stock |
| Patrick Yeramian | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.37 per share. | 17 Apr 2023 | 44,861 | 253,278 | - | 0.4 | 16,599 | Common Stock |
| Patrick Yeramian | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.94 per share. | 17 Apr 2023 | 300 | 208,417 | - | 30.9 | 9,282 | Common Stock |
| Patrick Yeramian | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.88 per share. | 17 Apr 2023 | 4,718 | 257,996 | - | 6.9 | 32,460 | Common Stock |
| George Mclean Milne | Director | Sale of securities on an exchange or to another person at price $ 31.86 per share. | 16 Mar 2023 | 33,084 | 863,937 | - | 31.9 | 1,053,901 | Common Stock |
| George Mclean Milne | Director | Sale of securities on an exchange or to another person at price $ 32.45 per share. | 16 Mar 2023 | 1,916 | 862,021 | - | 32.4 | 62,172 | Common Stock |
| James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 32.46 per share. | 16 Mar 2023 | 1,704 | 34,009 | - | 32.5 | 55,320 | Common Stock |
| James M. Frates | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.88 per share. | 16 Mar 2023 | 32,500 | 66,509 | - | 6.9 | 223,600 | Common Stock |
| James M. Frates | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2023 | 32,500 | 414,500 | - | - | Stock Option (right to buy) | |
| James M. Frates | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 97,500 | 97,500 | - | - | Stock Option (right to buy) | |
| James M. Frates | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 21,667 | 55,676 | - | 0 | Common Stock | |
| James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.86 per share. | 16 Mar 2023 | 30,796 | 35,713 | - | 31.9 | 981,139 | Common Stock |
| Patrick Yeramian | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2023 | 30,041 | 62,466 | - | - | Stock Option (right to buy) | |
| Patrick Yeramian | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.33 per share. | 16 Mar 2023 | 2,789 | 207,088 | - | 0.3 | 920 | Common Stock |
| Patrick Yeramian | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.37 per share. | 16 Mar 2023 | 30,041 | 237,129 | - | 0.4 | 11,115 | Common Stock |
| Patrick Yeramian | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.88 per share. | 16 Mar 2023 | 16,748 | 253,877 | - | 6.9 | 115,226 | Common Stock |
| Patrick Yeramian | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 31.85 per share. | 16 Mar 2023 | 52,211 | 201,666 | - | 31.8 | 1,662,842 | Common Stock |
| Patrick Yeramian | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.43 per share. | 16 Mar 2023 | 2,416 | 199,250 | - | 32.4 | 78,358 | Common Stock |
| Patrick Yeramian | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 9,167 | 208,417 | - | 0 | Common Stock | |
| Patrick Yeramian | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 41,250 | 41,250 | - | - | Stock Option (right to buy) | |
| Patrick Yeramian | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2023 | 2,789 | 0 | - | - | Stock Option (right to buy) | |
| Patrick Yeramian | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2023 | 16,748 | 48,252 | - | - | Stock Option (right to buy) | |
| Joshua Cohen | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 50,000 | 2,842,617 | - | 0 | Common Stock | |
| Joshua Cohen | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 225,000 | 225,000 | - | - | Stock Option (right to buy) | |
| Joshua Cohen | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 31.84 per share. | 16 Mar 2023 | 96,076 | 2,796,541 | - | 31.8 | 3,059,021 | Common Stock |
| Joshua Cohen | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 32.45 per share. | 16 Mar 2023 | 3,924 | 2,792,617 | - | 32.4 | 127,315 | Common Stock |
| Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 31.84 per share. | 16 Mar 2023 | 96,555 | 2,796,062 | - | 31.8 | 3,074,359 | Common Stock |
| Justin Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 225,000 | 225,000 | - | - | Stock Option (right to buy) | |
| Justin Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 50,000 | 2,842,617 | - | 0 | Common Stock | |
| Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 32.48 per share. | 16 Mar 2023 | 3,445 | 2,792,617 | - | 32.5 | 111,877 | Common Stock |
| Margaret Olinger | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 82,500 | 82,500 | - | - | Stock Option (right to buy) | |
| Margaret Olinger | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 18,333 | 232,688 | - | 0 | Common Stock | |
| Gina M. Mazzariello | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 82,500 | 82,500 | - | - | Stock Option (right to buy) | |
| Gina M. Mazzariello | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 18,333 | 55,747 | - | 0 | Common Stock | |
| Karen Firestone | Director | Purchase of securities on an exchange or from another person at price $ 31.99 per share. | 16 Mar 2023 | 1,000 | 1,000 | - | 32.0 | 31,990 | Common Stock |
| Karen Firestone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 27,403 | 27,403 | - | - | Stock Option (Right to Buy) | |
| Gina M. Mazzariello | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 34.49 per share. | 24 Feb 2023 | 3,586 | 37,414 | - | 34.5 | 123,672 | Common Stock |
| James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 36.79 per share. | 06 Jan 2023 | 822 | 34,009 | - | 36.8 | 30,240 | Common Stock |
| James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 36.08 per share. | 06 Jan 2023 | 1,836 | 34,831 | - | 36.1 | 66,241 | Common Stock |
| Patrick Yeramian | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 36.08 per share. | 06 Jan 2023 | 1,405 | 204,928 | - | 36.1 | 50,691 | Common Stock |
| Patrick Yeramian | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 36.79 per share. | 06 Jan 2023 | 629 | 204,299 | - | 36.8 | 23,140 | Common Stock |
| Joshua Cohen | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.79 per share. | 06 Jan 2023 | 1,846 | 2,892,617 | - | 36.8 | 67,912 | Common Stock |
| Joshua Cohen | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.08 per share. | 06 Jan 2023 | 4,122 | 2,894,463 | - | 36.1 | 148,717 | Common Stock |
| Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.79 per share. | 06 Jan 2023 | 1,846 | 2,892,617 | - | 36.8 | 67,912 | Common Stock |
| Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.08 per share. | 06 Jan 2023 | 4,122 | 2,894,463 | - | 36.1 | 148,717 | Common Stock |
| Margaret Olinger | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 36.08 per share. | 06 Jan 2023 | 1,660 | 215,098 | - | 36.1 | 59,891 | Common Stock |
| Margaret Olinger | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 36.79 per share. | 06 Jan 2023 | 743 | 214,355 | - | 36.8 | 27,334 | Common Stock |
| George Mclean Milne | Director | 31 Dec 2022 | 23,212 | 0 | - | - | Series C-2 Preferred Stock | ||
| George Mclean Milne | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 13,800 | 897,021 | - | 0 | Common Stock | |
| George Mclean Milne | Director | 31 Dec 2022 | 262,282 | 0 | - | - | Series A Preferred Stock | ||
| George Mclean Milne | Director | 31 Dec 2022 | 384,449 | 0 | - | - | Series B Preferred Stock | ||
| George Mclean Milne | Director | 31 Dec 2022 | 19,482 | 0 | - | - | Series C-1 Preferred Stock | ||
| George Mclean Milne | Director | 31 Dec 2022 | 689,425 | 910,821 | - | - | Common Stock | ||
| James M. Frates | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.88 per share. | 30 Dec 2022 | 5,000 | 36,667 | - | 6.9 | 34,400 | Common Stock |
| James M. Frates | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2022 | 5,000 | 447,000 | - | - | Stock Option (Right to Buy) | |
| George Mclean Milne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 19,000 | 19,000 | - | - | Stock Option (Right to Buy) | |
| Daphne Quimi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 19,000 | 19,000 | - | - | Stock Option (Right to Buy) | |
| Isaac Cheng | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 19,000 | 19,000 | - | - | Stock Option (Right to Buy) | |
| Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 19,000 | 19,000 | - | - | Stock Option (Right to Buy) | |
| Joshua Cohen | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2022 | 334,520 | 0 | - | - | Stock Option (right to buy) | |
| Joshua Cohen | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.37 per share. | 05 May 2022 | 334,520 | 2,898,585 | - | 0.4 | 123,772 | Common Stock |
| Justin Klee | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.37 per share. | 05 May 2022 | 334,520 | 2,898,585 | - | 0.4 | 123,772 | Common Stock |
| Justin Klee | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2022 | 334,520 | 0 | - | - | Stock Option (right to buy) | |
| Gina M. Mazzariello | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 41,000 | 41,000 | - | 0 | Common Stock | |
| Gina M. Mazzariello | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 182,000 | 182,000 | - | - | Stock Option (right to buy) | |
| James M. Frates | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2022 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| George Mclean Milne | Director | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 06 Jan 2022 | 26,315 | 221,396 | - | 19 | 499,985 | Common Stock |
| George Mclean Milne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 8,400 | 8,400 | - | - | Stock Option (Right to Buy) | |
| James M. Frates | Chief Financial Officer | 06 Jan 2022 | 19,482 | 0 | - | - | Series C-1 Preferred Stock | ||
| James M. Frates | Chief Financial Officer | 06 Jan 2022 | 19,482 | 19,482 | - | 0 | Common Stock | ||
| Daphne Quimi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 8,400 | 8,400 | - | - | Stock Option (Right to Buy) | |
| Isaac Cheng | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 8,400 | 8,400 | - | - | Stock Option (Right to Buy) | |
| Isaac Cheng | Director | 06 Jan 2022 | 1,621,544 | 0 | - | - | Series C-2 Preferred Stock | ||
| Isaac Cheng | Director | 06 Jan 2022 | 974,107 | 0 | - | - | Series C-1 Preferred Stock | ||
| Isaac Cheng | Director | 06 Jan 2022 | 6,410,964 | 0 | - | - | Series B Preferred Stock | ||
| Isaac Cheng | Director | 06 Jan 2022 | 1,409,035 | 0 | - | - | Series A Preferred Stock | ||
| Isaac Cheng | Director | 06 Jan 2022 | 6,410,964 | 7,819,999 | - | - | Common Stock | ||
| Isaac Cheng | Director | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 06 Jan 2022 | 6,578 | 6,578 | - | 19 | 124,982 | Common Stock |
| Isaac Cheng | Director | 06 Jan 2022 | 974,107 | 8,794,106 | - | - | Common Stock | ||
| Isaac Cheng | Director | 06 Jan 2022 | 1,621,544 | 10,415,650 | - | - | Common Stock | ||
| Isaac Cheng | Director | 06 Jan 2022 | 1,409,035 | 1,409,035 | - | - | Common Stock | ||
| Paul Fonteyne | Director | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 06 Jan 2022 | 3,947 | 3,947 | - | 19 | 74,993 | Common Stock |
| Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 8,400 | 8,400 | - | - | Stock Option (Right to Buy) | |
| Patrick Yeramian | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 28,333 | 206,333 | - | 0 | Common Stock | |
| Patrick Yeramian | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 127,500 | 127,500 | - | - | Stock Option (right to buy) | |
| Joshua Cohen | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 75,000 | 2,564,065 | - | 0 | Common Stock | |
| Joshua Cohen | Director, Co-Chief Executive Officer | 06 Jan 2022 | 4,870 | 2,489,065 | - | 0 | Common Stock | ||
| Joshua Cohen | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 337,500 | 337,500 | - | - | Stock Option (right to buy) | |
| Joshua Cohen | Director, Co-Chief Executive Officer | 06 Jan 2022 | 4,870 | 0 | - | - | Series C-1 Preferred Stock | ||
| Justin Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 337,500 | 337,500 | - | - | Stock Option (right to buy) | |
| Justin Klee | Director, Co-Chief Executive Officer | 06 Jan 2022 | 4,870 | 0 | - | - | Series C-1 Preferred Stock | ||
| Justin Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 75,000 | 2,564,065 | - | 0 | Common Stock | |
| Justin Klee | Director, Co-Chief Executive Officer | 06 Jan 2022 | 4,870 | 2,489,065 | - | 0 | Common Stock | ||
| Margaret Olinger | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 06 Jan 2022 | 6,842 | 216,758 | - | 19 | 129,998 | Common Stock |
| Margaret Olinger | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 28,333 | 209,916 | - | 0 | Common Stock | |
| Margaret Olinger | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 127,500 | 127,500 | - | - | Stock Option (right to buy) |